Proteoglycans as Target for an Innovative Therapeutic Approach in Chondrosarcoma: Preclinical Proof of Concept

Area of Science:

• Oncology
• Drug Delivery
• Biochemistry

Background:

• Chondrosarcoma treatment is limited by radio- and chemoresistance, stemming from its dense extracellular matrix and poor vascularity.
• Current management of advanced or metastatic chondrosarcoma remains a significant challenge, necessitating improved therapeutic strategies.

Purpose of the Study:

• To enhance the therapeutic index of chemotherapy for chondrosarcoma by developing a novel drug delivery system.
• To target proteoglycan (PG)-rich tissues characteristic of chondrosarcoma using a quaternary ammonium (QA) conjugated melphalan (Mel) derivative.

Main Methods:

• Utilized surface plasmon resonance to confirm the binding affinity of the QA carrier to aggrecan.
• Conducted in vivo biodistribution studies using radiolabeled melphalan and its QA derivative (Mel-QA) in an orthotopic Swarm rat chondrosarcoma model.
• Assessed antitumoral effects through tumor volume measurements, PG imaging, NMR spectroscopy, and histological analysis.

Main Results:

• The QA carrier demonstrated crucial binding to aggrecan, validating its targeting capability.
• In vivo studies showed rapid accumulation of [3H]-Mel-QA in both healthy cartilage and tumor tissues, with a higher tumor-to-tissue ratio for the QA derivative.
• Mel-QA conjugation improved melphalan's tolerability, significantly reducing side effects and enhancing the overall therapeutic index.

Conclusions:

• Quaternary ammonium conjugation represents a promising strategy to improve the therapeutic index of chemotherapy for chondrosarcoma.
• This approach enables targeted delivery to PG-rich tissues and enhances drug tolerability, potentially allowing for repeated chemotherapy cycles in chondrosarcoma patients.